Nothing Special   »   [go: up one dir, main page]

Krajewski et al., 1995 - Google Patents

Reduced expression of proapoptotic gene BAX is associated with poor response rates to combination chemotherapy and shorter survival in women with metastatic …

Krajewski et al., 1995

View PDF
Document ID
4551316536822298349
Author
Krajewski S
Blomqvist C
Franssila K
Krajewska M
Wasenius V
Niskanen E
Nordling S
Reed J
Publication year
Publication venue
Cancer research

External Links

Snippet

Bax is a homologue of Bcl-2 that promotes apoptosis. Bax protein levels were assessed by immunohistochemical methods in primary tumors derived from 119 women with metastatic breast cancer. These patients had received combination chemotherapy either with a once a …
Continue reading at www.academia.edu (PDF) (other versions)

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay
    • G01N33/574Immunoassay; Biospecific binding assay for cancer
    • G01N33/57407Specifically defined cancers
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals

Similar Documents

Publication Publication Date Title
Krajewski et al. Reduced expression of proapoptotic gene BAX is associated with poor response rates to combination chemotherapy and shorter survival in women with metastatic breast adenocarcinoma
Miyake et al. Motility-related protein-1 (MRP-1/CD9) reduction as a factor of poor prognosis in breast cancer
Hsu et al. Significance of proliferating cell nuclear antigen index in predicting pituitary adenoma recurrence
Chan et al. Immunohistochemical detection of P-glycoprotein: prognostic correlation in soft tissue sarcoma of childhood.
US6972170B1 (en) Markers for prostate cancer
Mueller et al. Differential regulation of bcl-2 and bcl-x by CD3, CD28, and the IL-2 receptor in cloned CD4+ helper T cells. A model for the long-term survival of memory cells.
Vargas‐Roig et al. Heat shock protein expression and drug resistance in breast cancer patients treated with induction chemotherapy
Sehgal et al. Transforming growth factor β1 stimulates contrasting responses in metastatic versus primary mouse prostate cancer-derived cell lines in vitro
KR20190015408A (en) Anti-PD-1 antibody for use in methods of treating tumors
CN112972675A (en) Use of anti-PD-1 antibodies in the treatment of tumors
Choi et al. The regulation of apoptosis by activin and transforming growth factor-β in early neoplastic and tumorigenic ovarian surface epithelium
US20220193193A1 (en) Methods for identification, assessment, prevention, and treatment of metabolic disorders using slit2
Treish et al. Pharmacology and therapeutic use of trastuzumab in breast cancer
US7244565B2 (en) Gene shinc-3 and diagnostic and therapeutic uses thereof
US7348418B2 (en) Carcinoma-related genes and polypeptides and methods of use thereof
Arends et al. Gastrointestinal cancer‐associated antigen (GICA) immunoreactivity in colorectal carcinoma in relation to patient survival
KR102645036B1 (en) Composition for diagnosing anti-cancer medicine resistance and kit comprising the same
Scott et al. Genes mediating programmed cell death: an immunohistochemical study of bcl-2, c-myc and p53 expression in colorectal neoplasia
Hill et al. Identification of a distinctive p‐glycoprotein‐mediated resistance phenotype in human ovarian carcinoma cells after their in vitro exposure to fractionated x‐irradiation
KR20170082537A (en) Predicting response to a vegf antagonist
WO2014017106A1 (en) Compositions Comprising RAC Mutants, and Methods of Use Thereof
Oda et al. Reverse transcriptase-polymerase chain reaction amplification of MDR1 gene expression in adult soft tissue sarcomas
EP3460476B1 (en) Biomarker composition comprising lrp-1 as active ingredient, for diagnosis of radiation-resistant cancer or prediction of radiation therapy prognosis
US20070106065A1 (en) TAT- 001 and methods of assessing and treating cancer
Matias‐Guiu et al. Expression of the ret proto‐oncogene in phaeochromocytoma. An in situ hybridization and northern blot study